Literature DB >> 3352269

Testing chemotherapeutic combinations in the Human Tumor Colony--Forming Assay.

V K Sondak1, E L Korn, D L Morton, D H Kern.   

Abstract

A total of 362 tumor specimens were tested in the Human Tumor Colony--Forming Assay for sensitivity to one of eight drug combinations and to each component drug as a single agent. Peak pharmacologically achievable concentrations of drug were used in continuous exposure. In 175 assays greater than 50% inhibition of colony formation, defined as in vitro sensitivity, was observed for at least one drug. The percent inhibition of the most active single agent closely approximated the percent inhibition of the combination. This relationship was maintained for all tumor types and combinations tested. Resistance in vitro to each drug in a combination predicted resistance to the combination. However, our data suggest that the higher activity of combination chemotherapy relative to single agents is due to an increased probability of finding an agent to which the tumor is sensitive, rather than to a synergistic interaction between drugs.

Entities:  

Mesh:

Year:  1988        PMID: 3352269     DOI: 10.1002/jso.2930370304

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

Review 1.  Combinatorial approaches to the prevention and treatment of HIV-1 infection.

Authors:  Vanessa Pirrone; Nina Thakkar; Jeffrey M Jacobson; Brian Wigdahl; Fred C Krebs
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

2.  In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study.

Authors:  Hee Seung Kim; Tae Joong Kim; Hyun Hoon Chung; Jae Weon Kim; Byung Gie Kim; Noh Hyun Park; Yong Sang Song; Duk Soo Bae; Soon Beom Kang
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-16       Impact factor: 4.553

Review 3.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

4.  In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.

Authors:  Kristina Wiberg; Kristina Carlson; Anna Aleskog; Rolf Larsson; Peter Nygren; Elin Lindhagen
Journal:  Med Oncol       Date:  2008-11-18       Impact factor: 3.064

5.  In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA).

Authors:  R Larsson; H Fridborg; J Kristensen; C Sundström; P Nygren
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.